Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Nichi-Iko to Offload AGs of Allegra and Plavix to Meiji Group
Nichi-Iko Pharmaceutical will transfer its authorized generic (AG) versions of three brands to a Meiji Group company, including one for Allegra (fexofenadine) — Japan’s first AG, approved in 2012 and launched the following year. Nichi-Iko, Sanofi, and Meiji Seika Pharma…
To read the full story
Related Article
- Sanofi, Nichi-Iko to Dissolve Joint Venture at Year-End
October 26, 2021
BUSINESS
- Rising Costs Squeeze Generic Firms, Spur Calls for Unprofitable Drug Re-Pricing in 2027
April 8, 2026
- BMS Files to Fully Localize Breyanzi Production in Japan
April 8, 2026
- Japan Ethical Drug Sales Surge 7.7% in February: Crecon
April 8, 2026
- Sanofi to Launch Voluntary Buyout Program, Targets General Medicines Unit
April 7, 2026
- Toho’s VC Arm Makes First Investment in US AI Antibody Startup
April 7, 2026
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…